Graf Acquisition IV : NKGen Biotech, Inc. ( NKGen ), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV - Form 8-K

NKGen Biotech, Inc. , a clinical stage Natural Killer cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV




... | April 17, 2023

Related Keywords

Delaware ,United States ,New York Stock Exchange ,New York ,Texas ,Mexico ,American ,James Graf ,Tony Kuznik ,Sabrina Mckee ,Anthonya Kuznik ,Denise Chua ,Nasdaq ,Co Ltd ,York Stock Exchange ,White Case ,Nkgen Biotech Inc ,Exchange Commission ,Graf Acquisition Corp ,Natural Killer ,Graf Acquisition ,American Society ,Clinical Oncology Annual Meeting ,Association International Conference ,New York Stock Exchange Listed ,Business Combination ,Investigational New Drug Application ,Santa Ana ,Executive Chairman ,Minimum Cash Condition ,Nasdaq Stock Market ,Merger Agreement ,Current Report ,Additional Information About ,Trust Account ,Special Meeting ,Registration Statement ,Combination Special ,Business Combination Special ,Blanding Blvd ,Annual Report ,Securities Act ,Graf Acquisition Corp Iv Stock Exchange ,News ,Information ,Press Release ,Nkgen ,Linical ,Stage ,Natural ,Killer ,Fell ,Therapy ,Gas ,Ntered ,Into ,Berger ,Agreement ,Ith ,Raf ,Cquisition ,V Gfor Us3842721009 ,